close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

186.93 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Global Economic Headwinds Intensify as China's Q3 GDP Forecast Signals Year-Low Growth, Sending Ripples Through International Markets
The global economy is bracing for a significant deceleration in 2025, a trend intensified by persistent trade tensions and widespread policy uncertainties. At the heart of this growing fragility lies... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Kenvue Stock Climbs Premarket, Day After Record Slide On UK Lawsuit: Retail Bulls Remain Unshaken
Via Stocktwits
Meet the 5%-Yielding Dividend Stock That Could Soar in 2026
Kenvue could start to recover in 2026. 
Via The Motley Fool
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets. 
Via MarketBeat
Why Kenvue Stock Tumbled by 13% on Thursday
The company's baby powder product is under legal fire once again. 
Via The Motley Fool
Topics Lawsuit
Global Markets Brace for Impact as Investor Risk Aversion Escalates Amidst Geopolitical Tensions and Economic Headwinds
Global financial markets are currently navigating a treacherous landscape marked by a pronounced surge in investor risk aversion. As of October 16, 2025, a potent cocktail of persistent geopolitical... 
Via MarketMinute
Topics Bonds Economy World Trade
Global Markets Brace for Turbulence: Credit Concerns and Geopolitical Tensions Fuel Volatility
Global financial markets are currently gripped by a palpable sense of unease and heightened volatility as October 2025 unfolds. A complex interplay of escalating geopolitical tensions, persistent... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Kenvue's Dual Dilemma: Tylenol and Talc Fears Trigger Sector Jitters
New York, NY – October 16, 2025 – The Consumer Staples and Healthcare sectors of the S&P 500 are experiencing a notable day of underperformance, largely overshadowed by the precipitous stock plunge of... 
Via MarketMinute
Topics Death Government Lawsuit
Fed Signals Further Easing Amid Uneven Inflation and Softening Labor Market: SF FedViews Points to More Rate Cuts
The Federal Reserve Bank of San Francisco's latest "SF FedViews" publication, released on October 16, 2025, offers a nuanced picture of the U.S. economy, highlighting inconsistent progress on inflation... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
Johnson & Johnson Plunges Amidst Escalating Talc Litigation: Billions at Stake as Legal Battles Intensify
New York, NY – October 16, 2025 – Johnson & Johnson (NYSE: JNJ), once considered a stalwart of stability, is currently navigating turbulent waters, finding itself among the market's bottom performers... 
Via MarketMinute
Topics Bankruptcy Death Lawsuit
Kenvue (KVUE) Plunges Amidst Dual Headwinds: Tylenol Fears and Escalating Talc Litigation
Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has found itself at the bottom of today's market performance, with its stock price experiencing a significant decline. As... 
Via MarketMinute
Topics Government Lawsuit
Investors Retreat to Safety: US Fund Flows Signal Defensive Stance Amidst Market Uncertainty
As October 2025 progresses, a palpable shift in investor sentiment is evident across US financial markets, with recent fund flow data signaling a clear pivot towards defensive strategies. Faced with... 
Via MarketMinute
Topics Bonds Economy
Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy
Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson reports. 
Via Benzinga
Johnson & Johnson: Earnings Beat, High Technical Momentum, UK Talc Suits Loom
Johnson & Johnson's stock shows strong technical momentum following a modest earnings beat, but faces potential volatility due to ongoing UK talc lawsuits and a strategic orthopedics spinoff. 
Via Talk Markets
Topics Earnings Lawsuit
Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase
Via The Motley Fool
Topics Regulatory Compliance
Johnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims
Johnson & Johnson faces 3,000 UK lawsuits alleging asbestos-contaminated talcum powder caused cancer and concealed risks for decades. 
Via Benzinga
Topics Lawsuit
Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks
A legal claim involving 3,000 people has been reportedly filed against Johnson & Johnson (NYSE: JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder. 
Via Benzinga
Topics Lawsuit
Scott Bessent Says US Investment Boom 'Sustainable' Under Trump: 'The Only Thing Slowing Us Down...'
U.S. Treasury Secretary Scott Bessent credited the country's investment boom to President Donald Trump's policies on Wednesday, and expressed optimism about its sustainability, but said the government... 
Via Benzinga
Topics Government
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Investors should be able to count on these stocks to deliver steady and growing income over the long term. 
Via The Motley Fool
Johnson & Johnson Battles New UK Talc Cancer Claims Worth £1B After Massive US Verdict: Report
Meanwhile, analysts raised price targets on the stock following strong Q3 results and the planned orthopedic spin-off. 
Via Stocktwits
Topics Bankruptcy Death Lawsuit
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Dow Jones Stumbles Amidst Global Headwinds, Reflecting Cautious Market Sentiment
The Dow Jones Industrial Average (DJIA) concluded a volatile trading day on Wednesday, October 15, 2025, with a fractional dip, signaling a cautious, if not overtly negative, sentiment pervading the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Climate Change
Dividend Defenders: How Two Stalwart Stocks Weathered April's Market Squall
As the calendar turned to April 2025, financial markets found themselves in a precarious position, teetering on the brink of a full-blown bear market. Investor fears, fueled by persistent inflation,... 
Via MarketMinute
Topics Bonds Economy Energy
Dividend Duo Delights Investors: Meta Platforms and Johnson & Johnson Shine in 2025
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings
 
Via Benzinga
Wall Street's Earnings Momentum Fades, Market Dips Amidst Trade Tensions
Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which... 
Via MarketMinute
Topics Economy Supply Chain World Trade
Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst
Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing fair valuation. 
Via Benzinga
2 Dividend Stocks I'm Very Thankful I Owned This Year
I don't intend to sell my shares of these companies anytime soon. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off
Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today